Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial

Kenshi Suzuki, Chang Ki Min, Kihyun Kim, Je Jung Lee, Hirohiko Shibayama, Po Shen Ko, Shang Yi Huang, Sin Syue Li, Bifeng Ding, Monica Khurana, Shinsuke Iida

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial'. Together they form a unique fingerprint.

Medicine & Life Sciences